On February 25, Vadim Shumkov, acting Governor of the Kurgan region, visited the production site of Sintez JSC (a joint asset of Marathon Group and Rostec's National Immunobiological Company) in Kurgan, and took part in a meeting that addressed the results of the plant's work in 2018. Vadim Shumkov awarded 19 plant employees with Certificates of Honor and Letters of Gratitude from the Ministry of Industry and Trade of the Russian Federation, noting their great dedication, and personal contributions, to the development of the industry, and to high production rates.
At the end of 2018, the plant's revenue exceeded 8.5 billion rubles (an increase of 16% compared to 2017), and Sintez became one of the top-3 fastest growing Russian pharmaceutical companies. According to Sintez CEO Sergey Klykov, these results were made possible due to a multi-phase production modernization program, reorganization of key departments, and adjustments to the plant's marketing strategy. As a result, drugs such as Diclofenac, Sultasin, Ceftriaxone and Rinorus experienced popular demand among consumers. Last year, the company introduced Angiorus, a new venotonic agent whose sales exceeded 270,000 units, totaling over 141 million rubles, by the end of December. Sintez hospital sector sales increased by about 20%.
"Our largest share of production and sales consists of dry powders for injections, followed by ointments and gels," said Sergey Klykov.
The Sintez CEO also noted that over the next two years, the company will be implementing a large-scale investment program worth 3.5 billion rubles. Most of these funds will be allocated to the modernization of the plant, and the development of new products, including those from its own substances. An agreement regarding joint development of the plant and partnership in the socio-economic sphere was signed by the administration of the Kurgan region, the National Immunobiological Company JSC, and Sintez JSC at the Russian Investment Forum in Sochi.